Reference change values to assess changes in concentrations of biomarkers of exposure in individuals participating in a cigarette-switching study

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 3, 2014, Pages 399-411

  Camacho, Oscar M ^a   Shepperd, Christopher J ^b   Eldridge, Alison ^b   Meyer, Ingo ^c   Proctor, Christopher J ^b  

^a Group Research and Development   (United Kingdom)

^b BRITISH AMERICAN TOBACCO   (United Kingdom)

^c Momentum Pharma Services   (Germany)

Author keywords

Biological variability; Biomarker of exposure; Cigarette; Reduced toxicant prototype (RTP); Reference change value; Smoke toxicant; Tobacco

Indexed keywords

3 HYDROXY 1 METHYLPROPYLMERCAPTURIC ACID; 3 HYDROXYPROPYLMERCAPTURIC ACID; BIOLOGICAL MARKER; CIGARETTE SMOKE; N NITROSOANATABINE; TAR; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FILTER; HUMAN; MONITORING; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED TOXICANT PROTOTYPE CIGARETTE; REFERENCE VALUE; SMOKING; TOBACCO; TOBACCO USE; URINE LEVEL;

ADULT; BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 84896120193     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0581     Document Type: Article

References (47)

1. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Clearing the smoke: assessing the scientific base for tobacco harm reduction. Washington, DC: National Academy of Sciences, 2001.
2. Doll R, Peto R, Wheatley K, Grey R, Sutherland I. Mortality in relation to smoking: 40 years observation on male British doctors. Br Med J 1994;309:901-11
3. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control 2003;12:424-30.
4. Burns DM, Dybing E, Gray N, Hecht SS, Anderson C, Sanner T, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organisation TobReg proposal. Tob Control 2008;17:132-41.
5. Public law 111-31 The family smoking prevention and tobacco control act. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/pdf/PLAW-111publ31. pdf. Accessed 22 July, 2013.
6. Scientific standards for studies on modified risk tobacco products. Available from: http://www.nap.edu/catalog. php?record-id#equal#13294. Accessed 22 July, 2013.
7. Public workshop: scientific evaluation of modified risk tobacco product (MRTP) applications. Available from: http://www.fda. gov/TobaccoProducts/ NewsEvents/ucm259201.htm. Accessed 22 July, 2013.
8. Shields PG, Connolly G, Cummings M, Djordjevic M, Hatsukami DK, Henningfield JE, et al. Providing a science base for the evaluation of tobacco products. Available from: https://gushare.georgetown.edu/lombardicomm/Website/ Tobacco/conceptual-framework.pdf. Accessed 22 July, 2013.
9. Hatsukami DK, Benowitz NL, Rennard SO, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006;8:600-22.
10. Hatsukami DK, Hanson K, Briggs A, Parascandola M, Genkinger JM, O'Connor R, et al. Clinical trials methods for evaluation of potential reduced exposure products. Cancer Epidemiol Biomarkers Prev 2009;18:3143-95.
11. Center for tobacco products, food and drug administration research priorities. Available from: http://www.fda.gov/downloads/TobaccoProducts/ NewsEvents/UCM293998.pdf. Accessed 22 July, 2013.
12. Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, et al. Effect of differing levels of tobacco-specific nitrosomines in cigarette smoke on the levels of biomarkers in smokers. Cancer Epidemiol Biomarkers Prev 2010;19:1389-98.
13. Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, et al. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbonfiltered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res 2008;10:1761-72.
14. Shepperd CJ, Eldridge A, Camacho OM, McAdam K, Proctor CJ, Meyer I. Changes in levels of biomarkers of exposure observed in a controlled study of smokers switched from conventional to reduced toxicant prototype cigarettes. Regul Toxicol Pharmacol 2013;66:147-62.
15. McAdam KG, Gregg EO, Bevan M, Dittrich DJ, Hemsley S, Liu C, et al. Design and chemical evaluation of reduced machine yield cigarettes. Regul Toxicol Pharmacol 2012;62:138-50.
16. Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M. A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. Regul Toxicol Pharmacol 2009;55:97-109.
17. Shepperd CJ, Eldridge AC, Errington G, Dixon M. A study to evaluate the effect on mouth level exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette. Regul Toxicol Pharmacol 2011;61(Suppl 3):S13-24.
18. Leischow SJ, Zeller M, Backinger CL. Research priorities and infrastructure needs of the Family smoking prevention and tobacco control act: science to inform FDA policy. Nicotine Tob Res 2012;14:1-6.
19. McAdam KG, Gregg EO, Liu C, Dittrich DJ, Duke MG, Proctor CJ. The use of a novel tobacco-substitute sheet and smoke dilution to reduce toxicant yields in cigarette smoke. Food Chem Toxicol 2011;49:1684-96.
20. Liu C, DeGrandpré Y, Porter A, Griffiths A, McAdam K, Voisine R, et al. The use of a novel tobacco treatment process to reduce toxicant yields in cigarette smoke. Food Chem Toxicol 2011;49:1904-17.
21. Branton PJ, McAdam KG, Duke MG, Liu C, Curle M, Mola M, et al. Use of classical adsorption theory to understand the dynamic filtration of volatile toxicants in cigarette smoke by active carbons. Absorption Sci Technol 2011;29:117-38.
22. Branton PJ, McAdam KG, Winter DB, Liu C, Duke MG, Proctor CJ. Reduction of aldehydes and hydrogen cyanide yields in mainstream cigarette smoke using an amine functionalised ion exchange resin. Chem Cent J 2011;5:15.
23. Kavvadias D, Scherer G, Urban M, Cheung F, Errington G, Shepperd J, et al. Simultaneous determination of four tobaccospecific N-nitrosamines (TSNA) in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 1999;877:1185-92.
24. Riedel K, Scherer G, Engl J, Hagedorn HW, Tricker AR. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol 2006;30:187-95.
25. Scherer G, Urban M, Hagedorn HW, Feng S, Kinser RD, Sarkar M, et al. Determination of two mercapturic acids related to crotonaldehyde in human urine: influence of smoking. Hum Exp Toxicol 2007;26:37-47.
26. Ramsauer B, Sterz K, Hagedorn HW, Engl J, Scherer G, McEwan M, et al. A liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the determination of phenolic polycyclic aromatic hydrocarbons (OH-PAH) in urine of non-smokers and smokers. Anal Bioanal Chem 2011;399:877-89.
27. Feng S, Kapur S, Sarkar M, Muhammad R, Mendes P, Newland K, et al. Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. Toxicol Lett 2007;173:101-6.
28. Sheldon C, Nachi R, Newland K, Lin P, Lee J. LC-MS/MS quantitation of acrolein biomarker, 3-HPMA (3-hydroxypropylmercapturic acid) in human urine. Association of Pharmaceutical Scientists, 2003, Poster.
29. International Federation of Clinical Chemistry (IFCC). Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987;5:645-56.
30. Clinical Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory approved guidelines, 3rd ed. Wayne, PA: Clinical Laboratory Standards Institute, 2008.
31. Harris EK, Yasaka T. On the calculation of "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
32. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
33. Fraser FG. Biological variation: from principles to practice. Washington, DC: AACC Press, 2001.
34. Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 2006;52:650-6.
35. Cheuvront SN, Fraser CG, Kenefick RW, Ely BR, Sawka MN. Reference change values for monitoring dehydration. Clin Chem Lab Med 2011;49:1033-7.
36. Widjaja A, Morris RJ, Levy JC, Frayn KN, Manley SE, Turner RC. Within-and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem 1999;45:561-6.
37. Fraser CG, Lippi G, Plebani M. Reference change values may need some improvement but are invaluable tools in laboratory medicine. Clin Chem Lab Med 2012;50:963-4.
38. Fraser GC. Reference change values: the way forward in monitoring. Ann Clin Biochem 2009;46:264-5.
39. Cooper G, DeJonge N, Ehrmeyer S, Yundt-Pacheco J, Jansen R, Ricós C, et al. Collective opinion paper on findings of the 2010 convocation of experts on laboratory quality. Clin Chem Lab Med 2011;49:793-802.
40. Fraser CG. Reference change values. Clin Chem Lab Med 2011;50:807-12.
41. Hecht SS, Carmella SG, Chen M, Koch JF, Miller AT, Murphy SE, et al. Quantitation of urinary metabolites of a tobaccospecific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
42. Ricós C, Iglesias N, García-Lario JV, Simón M, Cava F, Hernández A, et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007;44:343-52.
43. Fokkma MR, Hermann Z, Muskiet FA, Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602-3.
44. Omar F, Van der Watt GF, Pillay TS. Reference change values: how useful are they? J Clin Pathol 2008;61:426-7.
45. Petersen PH, Sandberg S, Fraser CG, Goldschmidt H. Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med 2001;39:160-5.
46. Carmella SG, Akerkar SA, Richie JP Jr., Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995;4:635-42.
47. Pinches MD, Betts CJ, Bickerton SJ, Beattie L, Burdett LD, Thomas HT, et al. Evaluation of novel urinary renal biomarkers: biological variation and reference change values. Toxicol Pathol 2012;40:541-9.